Yabao Pharmaceutical Group(600351.SH): Sitagliptin and Metformin Sustained-Release Tablets obtained drug registration certificate.

Yabao Pharmaceutical Group (600351.SH) announced that its wholly-owned subsidiary, Beijing Yabao Biopharmaceutical Co., Ltd. (hereinafter referred to as "Yabao Biopharm"), recently received the Drug Registration Certificate for Sitagliptin Metformin Extended-Release Tablets approved and issued by the National Medical Products Administration (NMPA) (Certificate No.: 2025S03027). Sitagliptin Metformin Extended-Release Tablets are used for the treatment of Type 2 diabetes in adults who are already receiving combined therapy with sitagliptin and metformin extended-release tablets. Sitagliptin Metformin Extended-Release Tablets were developed by MERCK SHARP DOHME and were approved for sale in the United States in 2012 under the brand name JANUMET XR. According to Minet statistics, the sales of Sitagliptin Metformin Tablets (), Sitagliptin Metformin Tablets (), and Sitagliptin Metformin Extended-Release Tablets in China in 2024 amounted to approximately 921 million yuan, with sales of 721 million yuan in public hospitals and 200 million yuan in retail pharmacies.